KCT0008001尚未招募未知
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Signed written informed consent
- •2.over 20 years of age
- •3.Histologically confirmed hepatocellular carcinoma(HCC)
- •4.at least one or more measurable intrahepatic viable HCC lesions by dynamic enhanced computed tomography (CT) or maganetic resonance images (MRI)
- •5.portal vein tumor thrombosis diagnosed by dynamic enhanced computed tomography (CT) or maganetic resonance images (MRI) with below finding
- •1) an intraluminal filling defect adjacent to the primary tumor in Vp2-4 portal vein(portal vein, hepatic vein, and/or inferior vena cava)
- •2) an enhancement of the filling defect on arterial phase and a washout on portal/delayed phases.
- •6.Child-Pugh class A
- •7.Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1
- •8.Life expectancy of at least 16 weeks
- •9.adequate bone marrow and liver function within 2 weeks from screening for study registration
- •-Hemoglobin = 9.0 g/dL
- •-Absolute neutrophil count (ANC) = 1,000/mm3
- •-Platelet count = 50,000/µL
- •-Total bilirubin < 2.5 mg/dL
- •-Serum albumin >2.8 g/dL
- •-Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) = 5 × upper limit of normal (ULN)
- •-Prothrombin time in INR = 1.8 × ULN
- •-Serum creatinine = 1.5 mg/dL
- •10.Women of childbearing potential and men must agree to use highly efficient contraception since signing of the informed consent form until at least 6 months (women) and 7 months (men) after the last study drug administration
- •11.If other selection conditions are satisfied and the exclusion criteria are not met, registration is possible even in case of N1 or M1.
- •12.Registration is possible even in the case of hepatic vein tumor infiltration if other selection conditions are satisfied and the exclusion criteria are not met
- •13.no limitation according to the size and number of tumors in the liver.
排除标准
- •1.previous history of systemic treatment for HCC (If systemic treatment for HCC has been performed at least once, it will not be enrolled in this study.) However, registration is permitted if the previous systemic treatment is for adjuvant purposes or treatment for other cancers. Also allowed if previous HCC treatment is local treatment. However, cases with a history of previous upper abdominal radiotherapy (including proton therapy and heavy particle therapy) are excluded.
- •2.any type of anticancer agent (including investigational) within 2 weeks before enrollment
- •3.Having active brain metastasis or leptomeningeal metastasis need surgery or steroid therapy
- •4.Moderate to severe or intractable ascites
- •5.A history or presence of hepatic encephalopathy
- •6.Presence of active bacterial infection
- •7.Active hepatitis B infection status, untreated active chronic hepatitis B or active hepatitis C infection
- •8.History of portal hypertension with bleeding within the past 6 months
- •9.Prior liver transplant
- •10.Uncontrolled severe medical comorbidity(Active tuberculosis, acute infection, acute ischemic heart disease, peptic ulcer disease)
- •11.Unhealed wound from surgery and other trauma
- •12.Uncontrolled electrolyte imbalance
- •13.Non-interruptible therapeutic use of anticoagulants or thrombolytics
- •14.History of uncontrolled or autoimmune disease, or immunocompromised
- •15.interstitial lung disease
- •16.Other malignant disease (a history of treated malignancy -other than HCC- is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding two years)
- •17.Mentally retarded/medically incapable of consent
研究者
相似试验
招募中
2 期
Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein InvasionHepatocellular CarcinomaPortal Vein ThrombosisNCT05625893Samsung Medical Center63
已完成
不适用
Radiotherapy with scanning beam protons for locally advanced prostate cancer or localised prostate cancer with risk factorsMalignant neoplasm of prostateProstate cancerCancerISRCTN78176828niversity Hospital Essen (Universitatsklinikum Essen) (Germany)240
招募中
2 期
A Prospective Clinical Trial of Proton Radiotherapy with 12 fractions for Patients with Prostate CancerProstate cancerJPRN-UMIN000045064arita Memorial Proton Center200
进行中（未招募）
Unknown
The neurocognitive benefits of proton beam therapy for patients with oligodendrogliomaBrain cancer, oligodendrogliomaCancerISRCTN13390479niversity of Leeds246
已完成
不适用
Efficacy and safety of proton beam therapy in patients with previously untreated hepatocellular carcinomaHepatocellular carcinomaJPRN-UMIN000025342niversity of Tsukuba129